SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 94 filers reported holding SYROS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $222,000 | +39.6% | 186,366 | +282.9% | 0.00% | – |
| Q4 2021 | $159,000 | -61.0% | 48,674 | -46.7% | 0.00% | -100.0% |
| Q3 2021 | $408,000 | -37.8% | 91,278 | -24.2% | 0.00% | 0.0% |
| Q2 2021 | $656,000 | -58.3% | 120,354 | -42.8% | 0.00% | -75.0% |
| Q1 2021 | $1,574,000 | +4.3% | 210,375 | +51.3% | 0.00% | 0.0% |
| Q4 2020 | $1,509,000 | +11.2% | 139,034 | -9.4% | 0.00% | -20.0% |
| Q3 2020 | $1,357,000 | -48.5% | 153,508 | -37.9% | 0.01% | -61.5% |
| Q2 2020 | $2,633,000 | +1655.3% | 246,997 | +1038.2% | 0.01% | – |
| Q4 2019 | $150,000 | -11.2% | 21,700 | +17.1% | 0.00% | -100.0% |
| Q1 2019 | $169,000 | -36.5% | 18,539 | -61.2% | 0.00% | 0.0% |
| Q4 2018 | $266,000 | -60.9% | 47,756 | -16.3% | 0.00% | -50.0% |
| Q3 2018 | $680,000 | -43.1% | 57,081 | -51.3% | 0.00% | -50.0% |
| Q2 2018 | $1,196,000 | +480.6% | 117,122 | +452.5% | 0.00% | +300.0% |
| Q4 2017 | $206,000 | +19.1% | 21,197 | +80.3% | 0.00% | 0.0% |
| Q3 2017 | $173,000 | – | 11,758 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,439,895 | $18,747,000 | 4.66% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $31,528,000 | 2.07% |
| Omega Fund Management, LLC | 2,274,831 | $12,398,000 | 1.40% |
| Altium Capital Management LP | 1,076,942 | $5,869,000 | 1.36% |
| Samsara BioCapital, LLC | 2,189,199 | $10,599,000 | 1.31% |
| Sio Capital Management, LLC | 800,000 | $4,360,000 | 1.08% |
| Flagship Pioneering Inc. | 2,938,494 | $16,015,000 | 0.20% |
| EcoR1 Capital, LLC | 1,000,000 | $5,450,000 | 0.20% |
| Artal Group S.A. | 1,700,000 | $9,265,000 | 0.19% |
| ACT CAPITAL MANAGEMENT, LLC | 52,500 | $287,000 | 0.15% |